摘要
近年来,随着对肿瘤生物学认识的深入,以贝伐珠单抗、西妥昔单抗为代表的分子靶向治疗药物正逐渐丰富着晚期结直肠癌的治疗选择。贝伐珠单抗是一种人源化、人鼠嵌合抗血管内皮生长因子的单克隆抗体,是第一个被美国FDA批准用于治疗晚期结直肠癌患者的抗血管生成药物,以贝伐珠单抗为基础进行的临床研究也证实了它能改善晚期结直肠癌患者的生存期。全文通过回顾近年来发布的结直肠癌治疗领域有关贝伐珠单抗的临床研究,对其在晚期结直肠癌一线、二线和维持治疗以及在结直肠癌术后辅助治疗领域中的应用做一系统综述。
With the further understanding of tumor biology,targeted therapy agents,such as bevacizumab and cetuximab have been developed for treatment of metastatic colorectal cancer. Beva-cizumab is a humanized,human-mouse chimeric Ig G1 monoclonal antibody against VEGF-A. It is the first anti-angiogenic agent approved by US FDA for the treatment of metastatic colorectal cancer in combination with chemotherapy. Dozens of randomized clinical trials have confirmed its ef-fect in prolonging the overall survival of patients with metastatic colorectal cancer. This article re-views the recent progress on application of bevacizmab in first-line treatment,second-line treatment,maintenance treatment and adjuvant treatment for patients with advanced colorectal cancer.
出处
《中国肿瘤》
CAS
2016年第7期534-541,共8页
China Cancer
基金
国家自然科学基金<STIM1相关信号通路调控结直肠癌转移机制研究>(81472300)
关键词
结直肠癌
贝伐珠单抗
治疗
colorectal cancer
bevacizumab
treatment
